Travere Therapeutics Quote - TVTX

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

14.92

Bid

12.90

Ask

15.80

Volume

1,101,182

14.56 Day's Range 15.00

5.12 52 Week Range 25.29

Market Cap

1.324B

Previous Close

14.57

Open

14.56

Last Trade

14.92

Last Trade Time

Financial Volume

US$ 16,164,919

VWAP

14.6796

Average Volume (3m)

1,797,689

Shares Outstanding

88,739,826

Dividend Yield

PE Ratio

-4.12

Earnings Per Share (EPS)

-3.62

Revenue

233.18M

Net Profit

-321.55M

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomer... Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

travere.com

Headquarters

Lewes, Delaware, USA

Founded

Travere Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TVTX. The last closing price for Travere Therapeutics was US$14.57. Over the last year, Travere Therapeutics shares have traded in a share price range of US$ 5.12 to US$ 25.29.

Travere Therapeutics currently has 88,739,826 shares outstanding. The market capitalization of Travere Therapeutics is US$1.29 billion. Travere Therapeutics has a price to earnings ratio (PE ratio) of -4.12.

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

Late-breaking oral presentation details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS Data...

Form 8-K - Current report

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.42	2.89655172414	14.5	15.23	12.9	1561307	14.35005302	CS
4	-5.57	-27.1839921913	20.49	21.35	12.9	1963908	16.99750746	CS
12	-6.04	-28.8167938931	20.96	25.29	12.9	1797689	19.59433354	CS
26	-3.13	-17.3407202216	18.05	25.29	12.9	1517763	18.98372789	CS
52	8.68	139.102564103	6.24	25.29	5.12	1501550	14.77791932	CS
156	-14.86	-49.8992612492	29.78	30.35	5.12	1299755	15.23279145	CS
260	-10.23	-40.675944334	25.15	33.0899	5.12	1122284	16.86659588	CS

TVTX - Frequently Asked Questions (FAQ)

What is the current Travere Therapeutics share price?

The current share price of Travere Therapeutics is US$ 14.92

How many Travere Therapeutics shares are in issue?

Travere Therapeutics has 88,739,826 shares in issue

What is the market cap of Travere Therapeutics?

The market capitalisation of Travere Therapeutics is USD 1.29B

What is the 1 year trading range for Travere Therapeutics share price?

Travere Therapeutics has traded in the range of US$ 5.12 to US$ 25.29 during the past year

What is the PE ratio of Travere Therapeutics?

The price to earnings ratio of Travere Therapeutics is -4.12

What is the cash to sales ratio of Travere Therapeutics?

The cash to sales ratio of Travere Therapeutics is 5.68

What is the reporting currency for Travere Therapeutics?

Travere Therapeutics reports financial results in USD

What is the latest annual turnover for Travere Therapeutics?

The latest annual turnover of Travere Therapeutics is USD 233.18M

What is the latest annual profit for Travere Therapeutics?

The latest annual profit of Travere Therapeutics is USD -321.55M

What is the registered address of Travere Therapeutics?

The registered address for Travere Therapeutics is 16192 COASTAL HWY, LEWES, DELAWARE, 19958

What is the Travere Therapeutics website address?

The website address for Travere Therapeutics is travere.com

Which industry sector does Travere Therapeutics operate in?

Travere Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MSGMMotorsport Games Inc	US$ 2.69 (140.18%)	37M
SXTCChina SXT Pharmaceuticals Inc	US$ 2.11 (113.37%)	51.73M
ADGMAdagio Medical Holdings Inc	US$ 1.68 (81.98%)	115.48M
PNBKPatriot National Bancorp Inc	US$ 3.28 (73.54%)	1.57M
RTCBaijiayun Group Ltd	US$ 0.3601 (67.49%)	187.02M
LXEHLixiang Education Holding Company Ltd	US$ 8.25 (-64.11%)	1.55M
CLIKClick Holdings Ltd	US$ 0.355 (-48.18%)	13.52M
IOTRiOThree Ltd	US$ 1.1409 (-38.33%)	3.93M
FMTOFemto Technologies Inc	US$ 0.0191 (-35.47%)	198.4M
SISIShineco Inc	US$ 0.5809 (-35.07%)	824.91k
DMNDamon Inc	US$ 0.0034 (9.68%)	409.39M
STSSSharps Technology Inc	US$ 0.03195 (20.57%)	391.8M
SUNESUNation Energy Inc	US$ 0.0176 (-10.20%)	349.4M
NVDANVIDIA Corporation	US$ 101.49 (-2.87%)	292.48M
HTZHertz Global Holdings Inc	US$ 8.205 (43.70%)	266.91M